Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/101011
DC FieldValueLanguage
dc.contributor.authorDeus, Cláudia M.-
dc.contributor.authorPereira, Susana P.-
dc.contributor.authorCunha-Oliveira, Teresa-
dc.contributor.authorTeixeira, José-
dc.contributor.authorSimões, Rui F.-
dc.contributor.authorCagide, Fernando-
dc.contributor.authorBenfeito, Sofia-
dc.contributor.authorBorges, Fernanda-
dc.contributor.authorRaimundo, Nuno-
dc.contributor.authorOliveira, Paulo J.-
dc.date.accessioned2022-07-25T23:08:44Z-
dc.date.available2022-07-25T23:08:44Z-
dc.date.issued2021-
dc.identifier.issn22132317pt
dc.identifier.urihttps://hdl.handle.net/10316/101011-
dc.description.abstractParkinson's Disease (PD) is a neurodegenerative disorder affecting more than 10 million people worldwide. Currently, PD has no cure and no early diagnostics methods exist. Mitochondrial dysfunction is presented in the early stages of PD, and it is considered an important pathophysiology component. We have previously developed mitochondria-targeted hydroxycinnamic acid derivatives, presenting antioxidant and iron-chelating properties, and preventing oxidative stress in several biological models of disease. We have also demonstrated that skin fibroblasts from male sporadic PD patients (sPD) presented cellular and mitochondrial alterations, including increased oxidative stress, hyperpolarized and elongated mitochondria and decreased respiration and ATP levels. We also showed that forcing mitochondrial oxidative phosphorylation (OXPHOS) in sPD fibroblasts uncovers metabolic defects that were otherwise hidden. In this work, we tested the hypothesis that a lead mitochondria-targeted hydroxycinnamic acid derivative would revert the phenotype found in skin fibroblasts from sPD patients. Our results demonstrated that treating human skin fibroblasts from sPD patients with non-toxic concentrations of AntiOxCIN4 restored mitochondrial membrane potential and mitochondrial fission, decreased autophagic flux, and enhanced cellular responses to stress by improving the cellular redox state and decreasing reactive oxygen species (ROS) levels. Besides, fibroblasts from sPD patients treated with AntiOxCIN4 showed increased maximal respiration and metabolic activity, converting sPD fibroblasts physiologically more similar to their sex- and age-matched healthy controls. The positive compound effect was reinforced using a supervised machine learning model, confirming that AntiOxCIN4 treatment converted treated fibroblasts from sPD patients closer to the phenotype of control fibroblasts. Our data points out a possible mechanism of AntiOxCIN4 action contributing to a deeper understanding of how the use of mitochondria-targeted antioxidants based on a polyphenol scaffold can be used as potential drug candidates for delaying PD progression, validating the use of fibroblasts from sPD patients with more active OXPHOS as platforms for mitochondria-based drug development.pt
dc.description.sponsorshipThe work was funded by the Montepio Foundation under the project “An Epigenetic Engineering Approach to Reverse the Parkinson Disease Cell State (PD-state)” (CPD0028001; 2015). This work was also financed by the European Regional Development Fund (ERDF), through the [1Centro2020] Regional Operational Programme under project CENTRO-07-ST24-FEDER-002008 and through the COMPETE 2020-Operational Programme for Competitiveness and Internationalisation and Portuguese national funds via FCT–Fundaçao ˜ para a Ciˆencia e a Tecnologia, under project(s) PTDC/BIA-MOL/28607/2017 (POCI-01-0145- FEDER-028607), PTDC/BTM-SAL/29297/2017 (POCI-01-0145-FEDER029297), PTDC/MED-FAR/29391/2017 (POCI-01-0145-FEDER029391, UIDB/04539/2020 and UIDP/04539/2020). CMD (SFRH/BD/ 100341/2014) was supported by FCT PhD-fellowship and SPP (SFRH/ BPD/116061/2016) was supported by FCT Pos-Doctoral fellowship. NR was supported by European Research Council Starting Grant 337327 MitoPexLyso and Deutsche Forschungsgemeinschaft SFB1190–P02. This work has also received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 857524. The authors are extremely grateful to the Biomaterials and Stem Cell-Based Therapeutics Laboratory for helping with microscopy assays. Fig. 13 drawn with BioRender.pt
dc.language.isoengpt
dc.publisherElsevierpt
dc.relationinfo:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC/BIA-MOL/28607/2017/PT/Redox-active phytochemicals triggering mitochondrial hormesis: developing a new generation of cosmetic active ingredientspt
dc.relationinfo:eu-repo/grantAgreement/FCT/PTDC/BIA-MOL/28607/2017pt
dc.relationinfo:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC/BTM-SAL/29297/2017/PT/Development and validation of innovative screening methods for mitochondrial health modulatorspt
dc.relationinfo:eu-repo/grantAgreement/FCT/PTDC/BTM-SAL/29297/2017pt
dc.relationinfo:eu-repo/grantAgreement/FCT/9471 - RIDTI/PTDC/MED-FAR/29391/2017/PT/Development of Novel Mitochondria-Targeted Antioxidants for Improving SOD1-Familial Amyotrophic Lateral Sclerosis Phenotypept
dc.relationinfo:eu-repo/grantAgreement/FCT/PTDC/MED-FAR/29391/2017pt
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB/04539/2020/PTpt
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP/04539/2020/PTpt
dc.relationinfo:eu-repo/grantAgreement/FCT/POR_CENTRO/SFRH/BD/100341/2014/PT/An Innovative Epigenetic Engineering Approach to Reverse the Parkinson Disease Cell Statept
dc.relationinfo:eu-repo/grantAgreement/FCT/POR_NORTE/SFRH/BPD/116061/2016/PT/Exercising the Future: Voluntary Exercise During Gestational Diabetes to Improve Cardiac Function and Mitochondrial Function in the Offspringpt
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/857524/EU/Multidisciplinary Institute of Ageing - Portugalpt
dc.relationinfo:eu-repo/grantAgreement/EC/FP7/337327/EU/Mitochondria, Peroxisomes and Lysosomes - the "menage a trois" of cellular metabolismpt
dc.rightsopenAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt
dc.subjectHuman skin fibroblastspt
dc.subjectMetabolismpt
dc.subjectMitochondriapt
dc.subjectMitochondriotropic antioxidantpt
dc.subjectSporadic Parkinson's diseasept
dc.subject.meshCaffeic Acidspt
dc.subject.meshFibroblastspt
dc.subject.meshHumanspt
dc.subject.meshMalept
dc.subject.meshMitochondriapt
dc.subject.meshOxidative Stresspt
dc.subject.meshParkinson Diseasept
dc.titleA mitochondria-targeted caffeic acid derivative reverts cellular and mitochondrial defects in human skin fibroblasts from male sporadic Parkinson's disease patientspt
dc.typearticle-
degois.publication.firstPage102037pt
degois.publication.titleRedox Biologypt
dc.peerreviewedyespt
dc.identifier.doi10.1016/j.redox.2021.102037pt
degois.publication.volume45pt
dc.date.embargo2021-01-01*
uc.date.periodoEmbargo0pt
item.openairetypearticle-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.grantfulltextopen-
item.fulltextCom Texto completo-
crisitem.author.researchunitCNC - Center for Neuroscience and Cell Biology-
crisitem.author.orcid0000-0002-7382-0339-
crisitem.author.orcid0000-0002-5982-8983-
Appears in Collections:I&D CNC - Artigos em Revistas Internacionais
IIIUC - Artigos em Revistas Internacionais
I&D MIA PORTUGAL - Artigos em Revistas Internacionais
Files in This Item:
File Description SizeFormat
Deus et al. - 2021 - Redox Biology(2)-annotated.pdf15.6 MBAdobe PDFView/Open
Show simple item record

SCOPUSTM   
Citations

6
checked on Nov 17, 2022

WEB OF SCIENCETM
Citations

7
checked on Nov 15, 2022

Page view(s)

112
checked on Mar 26, 2024

Download(s)

71
checked on Mar 26, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons